Skip to content
LATEST
Markets

Summit Therapeutics co-CEO reports spouse exercised 300,000 options

The transaction adds to Robert W. Duggan’s direct position of more than 573 million shares while company stock fell nearly 6% in regular trading.

Summit Therapeutics co-CEO reports spouse exercised 300,000 options

Summit Therapeutics Inc. Co-Chief Executive Officer Robert W. Duggan disclosed on Nov. 20 that his spouse exercised options to acquire 300,000 shares of common stock at $1.06 each.

The transaction, revealed in a Securities and Exchange Commission Form 4 filing, expands the executive family's holdings as Summit shares fell 5.87% to close at $9.95 in regular trading on Friday.

Following the derivative conversion, Duggan's spouse beneficially owns 831,000 shares indirectly and retains options to purchase another 500,000 shares that expire in June 2032. Duggan directly owns 573,883,879 common shares in the biotechnology company, according to the regulatory filing.

The filing also listed indirect holdings tied to Duggan's spouse, including 25,824,474 shares held by the Mahkam Zanganeh Revocable Trust and 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust. Duggan disclaimed beneficial ownership of the indirect securities except to the extent of his pecuniary interest.

The option was originally granted in June 2022 and modified in April 2025 to follow service-based vesting schedules. In extended trading following the disclosure on Friday, Summit shares traded up 1.21% to $10.07.

Source: Form 4 securities filing, U.S. Securities and Exchange Commission, Nov. 20, 2026.

More stories

Latest news